A Quality Approach to Blinatumomab Delivery in Pediatric Oncology: A Children's Oncology Group Study.

IF 1 4区 医学 Q3 NURSING
Kathleen E Montgomery, Sue Zupanec, Christine Yun, Maki Okada, Holly Kubaney, Erin Feehily, Janice S Withycombe
{"title":"A Quality Approach to Blinatumomab Delivery in Pediatric Oncology: A Children's Oncology Group Study.","authors":"Kathleen E Montgomery, Sue Zupanec, Christine Yun, Maki Okada, Holly Kubaney, Erin Feehily, Janice S Withycombe","doi":"10.1177/27527530241267303","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Blinatumomab is a promising immunotherapy agent that has been shown to improve survival outcomes in children diagnosed with relapsed B-lineage acute lymphoblastic leukemia. Expanded use of blinatumomab in the treatment of childhood cancer is expected; however, clinician perspectives regarding administering this agent in healthcare and home settings have not been explored. <b>Method:</b> Semistructured interviews were conducted with clinicians (<i>N</i> = 13) from pediatric institutions across the United States and Canada. Qualitative data were analyzed using a constant comparative analysis three-stage method. <b>Results:</b> Participants were primarily nurses (92%), female (77%), and had greater than 10 years of pediatric oncology experience. The selective code and overarching theme identified was \"A quality approach to blinatumomab delivery in pediatric oncology.\" Clinicians described detailed processes that were created and implemented to promote a common goal of safe blinatumomab administration across the continuum of care. Clinicians shared how they engaged in planning activities and considered a variety of factors prior to and during blinatumomab administration. Clinicians also expressed a need to reflect and evaluate on previous patient experiences to create new or revise existing processes and workflows. Communication was also central to clinicians' work. Clinicians provided recommendations to assist others with blinatumomab administration and offered suggestions for items that could help with implementing future clinical trials containing similar agents. <b>Discussion:</b> Findings suggest nurses are pivotal to establishing processes which support safe administration of immunotherapies, such as blinatumomab, while also considering patient-specific needs and promoting quality of life.</p>","PeriodicalId":29692,"journal":{"name":"Journal of Pediatric Hematology-Oncology Nursing","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Hematology-Oncology Nursing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/27527530241267303","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Blinatumomab is a promising immunotherapy agent that has been shown to improve survival outcomes in children diagnosed with relapsed B-lineage acute lymphoblastic leukemia. Expanded use of blinatumomab in the treatment of childhood cancer is expected; however, clinician perspectives regarding administering this agent in healthcare and home settings have not been explored. Method: Semistructured interviews were conducted with clinicians (N = 13) from pediatric institutions across the United States and Canada. Qualitative data were analyzed using a constant comparative analysis three-stage method. Results: Participants were primarily nurses (92%), female (77%), and had greater than 10 years of pediatric oncology experience. The selective code and overarching theme identified was "A quality approach to blinatumomab delivery in pediatric oncology." Clinicians described detailed processes that were created and implemented to promote a common goal of safe blinatumomab administration across the continuum of care. Clinicians shared how they engaged in planning activities and considered a variety of factors prior to and during blinatumomab administration. Clinicians also expressed a need to reflect and evaluate on previous patient experiences to create new or revise existing processes and workflows. Communication was also central to clinicians' work. Clinicians provided recommendations to assist others with blinatumomab administration and offered suggestions for items that could help with implementing future clinical trials containing similar agents. Discussion: Findings suggest nurses are pivotal to establishing processes which support safe administration of immunotherapies, such as blinatumomab, while also considering patient-specific needs and promoting quality of life.

在儿科肿瘤学中使用 Blinatumomab 的质量方法:儿童肿瘤学小组的一项研究。
背景:Blinatumomab 是一种很有前景的免疫疗法药物,已被证明能改善复发 B 系急性淋巴细胞白血病患儿的生存状况。在治疗儿童癌症时,有望扩大 Blinatumomab 的使用范围;然而,临床医生对在医疗保健和家庭环境中使用这种药物的看法尚未得到探讨。研究方法对来自美国和加拿大儿科机构的临床医生(N = 13)进行了半结构式访谈。采用三阶段恒定比较分析法对定性数据进行分析。结果:参与者主要是护士(92%)、女性(77%),并拥有 10 年以上的儿科肿瘤学经验。所确定的选择性代码和首要主题是 "在儿科肿瘤学中提供优质 blinatumomab 的方法"。临床医生详细介绍了为促进在整个治疗过程中安全使用 blinatumomab 这一共同目标而创建和实施的流程。临床医生们分享了他们如何在使用 blinatumomab 之前和使用过程中参与规划活动并考虑各种因素。临床医生们还表示需要对以往的患者经验进行反思和评估,以创建新的或修改现有的流程和工作流程。沟通也是临床医生工作的核心。临床医生提出了协助他人进行 blinatumomab 给药的建议,并就有助于未来实施含有类似药物的临床试验的项目提出了建议。讨论:研究结果表明,护士在建立支持免疫疗法(如 blinatumomab)安全用药的流程方面起着关键作用,同时还要考虑患者的具体需求并提高生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.30
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信